Lexeo Therapeutics, Inc. (LXEO) stock
Close on Nov 12, 2026Market cap $238.76MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $238.76M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.02
- Dividend yield
- –
- Free cash flow yield
- -37.15%
Fundamentals
- Net income
- -$87.30M
- EPS, diluted
- -$1.15
- Free cash flow
- -$88.70M
- Book value per share
- $2.75
- Diluted shares
- 86M
Trading
- Next earnings
- Q3 FY2026, expected soon
- Previous close
- $3.07
- Open
- $3.02
- Day's range
- $2.82 – $3.05
- Volume
- 1,717,456
- Average volume (20 days)
- 1,297,739
- Index membership
- Russell 2000 (since Mar 2024), Russell 3000 (since May 2024)
- Beta (5 years)
- 2.17
- 52-week range
- $2.55 – $10.99
- RSI (14 days)
- 43.6
- Volatility (1 year)
- 70.9%
- Relative volume
- 1.41×
- WACC
- 15.7%
On 1 of our idea list: More cash than they're worth
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2023, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | LXEO | S&P 500 | Difference | LXEO per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -4.3% | -2.7% | −1.6 pts | ||
| 3 months | -40.2% | -1.7% | −38.5 pts | ||
| Year to date | -70.7% | +11.9% | −82.6 pts | ||
| 1 year | -68.4% | +12.0% | −80.4 pts | ||
| 3 years | -73.0% | +78.2% | −151.2 pts | -35.4% | +21.2% |
Five years at a glance
Fiscal years 2021 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Lexeo Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- News
- News
- Results
- Results
- Update
- Update
About Lexeo Therapeutics
Biological Products, (No Diagnostic Substances)
Lexeo Therapeutics is a clinical-stage genetic medicine company that develops gene therapies for cardiovascular diseases with underlying genetic causes. Its therapeutic pipeline includes LX2006, an adeno-associated virus gene therapy candidate that delivers a functional frataxin gene to treat Friedreich ataxia cardiomyopathy. Another primary candidate, LX2020, delivers a functional PKP2 gene to address arrhythmogenic cardiomyopathy caused by PKP2 mutations. The company also develops LX2021 to provide functional connexin 43 protein for inherited cardiac muscle disorders. Operating within the biotechnology and genetic medicine sector, the company focuses on serving patients suffering from serious hereditary heart conditions.
Company profile, executives and historyLexeo Therapeutics stock: common questions
What is Lexeo Therapeutics's stock price?
LXEO closed at $2.91 on Nov 12, 2026, down 5.21% on the day. Over the past 52 weeks it traded between $2.55 and $10.99.
What is Lexeo Therapeutics's market cap?
Lexeo Therapeutics was worth $238.76M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is LXEO's P/E ratio?
Lexeo Therapeutics lost money over the twelve months to Jun 30, 2026 (diluted EPS -$1.15), so it has no meaningful P/E ratio.
Does Lexeo Therapeutics pay a dividend?
No. Lexeo Therapeutics has not paid a cash dividend over the last twelve months.
When does Lexeo Therapeutics report earnings next?
Lexeo Therapeutics's Q3 FY2026 results are due soon; the company has not yet filed them with the SEC.
How has LXEO stock performed over the past year?
Including dividends, LXEO returned -68.4% over the past year, against +12.0% for the S&P 500.
How many LXEO shares are sold short?
17M shares were sold short at the latest FINRA report, 21.01% of the float, or 12.7 days of average trading volume.
Who are Lexeo Therapeutics's competitors?
Companies most similar to Lexeo Therapeutics by business, industry and size include SLDB, TNYA, TSHA, TECX, MGTX.
See a number that looks wrong?